GHRP-2 (Pralmorelin)

GHRP-2 (Pralmorelin): Definition and Mechanism of Action

GHRP-2 (Pralmorelin) is a synthetic hexapeptide and growth hormone secretagogue that stimulates endogenous growth hormone release by activating the ghrelin receptor. Primarily used as a diagnostic tool for growth hormone deficiency, it is also researched for its metabolic effects without introducing exogenous hormones directly into the body.

This synthetic peptide consists of six amino acids (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) with a molecular weight of 817.97 g/mol. Developed in the 1990s by Cyril Bowers' group and later advanced by Kaken Pharmaceutical as KP-102, GHRP-2 signals the pituitary gland to release natural pulses of growth hormone. While listed as orally active in some databases, clinical applications typically utilize subcutaneous or intravenous administration for maximum bioavailability.

Mechanism of Action: How GHRP-2 Stimulates Growth Hormone

GHRP-2 works by mimicking the hunger hormone ghrelin and binding to the GHS-R1a receptor in the pituitary gland and hypothalamus. This activation triggers a rapid pulse of endogenous growth hormone while simultaneously suppressing somatostatin, the natural inhibitor of growth hormone secretion.

On a molecular level, GHRP-2 couples to Gq/11 proteins to activate the PLCβ/IP3 and protein kinase C pathways. This induces a sharp growth hormone pulse peaking between 15 and 60 minutes. Within the GHRP family, GHRP-2 is highly potent but also causes moderate co-stimulation of ACTH, cortisol, and prolactin-a profile weaker than GHRP-6 but stronger than Ipamorelin.

Clinical Efficacy and Research Results for GHRP-2

GHRP-2 is highly effective at acutely stimulating growth hormone secretion and increasing appetite in human trials. However, robust large-scale clinical data for long-term muscle growth or fat loss is currently lacking, and its validated use remains restricted to diagnostic hormone testing.

Research on healthy males confirms that GHRP-2 influences energy metabolism and increases food intake. Commercial databases often cite an appetite increase of approximately 36%, though the methodological background for this figure is often unclear. While animal models suggest potential for recovery, independent randomized controlled trials for off-label uses are missing.

GHRP-2 Dosage Protocols in Clinical and Research Contexts

Clinical diagnostic protocols for GHRP-2 typically involve a single intravenous bolus or subcutaneous infusion at rates like 1 µg/kg/h to measure pituitary response. Since there are no approved therapeutic dosing instructions in Europe or the USA, off-label research protocols vary and are strictly informational.

Studies show that growth hormone response is dose-dependent, but excessive doses do not linearly increase benefits. Instead, high doses primarily amplify side effects like water retention and cortisol spikes. Conservative research approaches emphasize starting with minimal effective doses to assess individual tolerance.

Reconstitution and Dosage Calculation for GHRP-2

GHRP-2 is typically sold as a lyophilized powder that requires reconstitution with bacteriostatic water before subcutaneous injection. Maintaining sterile conditions is vital, as contaminated solutions can lead to severe health complications from bacteria or endotoxins.

To reconstitute, a precise volume of bacteriostatic water is added to the vial; for example, 2 mL of water in a 5 mg vial creates a concentration of 2.5 mg (2500 mcg) per mL. Using a standard insulin syringe, a 100 mcg dose requires 4 units (0.04 mL). Harm reduction involves using sterile syringes and alcohol swabs to prevent localized infections.

Side Effects, Safety Risks, and Harm Reduction for GHRP-2

Common side effects of GHRP-2 include increased appetite, mild water retention, flushing, and moderate elevations in cortisol and prolactin. Sourcing from unregulated markets carries significant risks of infection or toxic reactions if sterility testing is bypassed.

GHRP-2 is generally better tolerated than GHRP-6 but more likely to cause systemic stress via cortisol and prolactin than Ipamorelin. A major concern is the lack of comprehensive human metabolism data, leaving long-term safety profiles incomplete.

• Sourcing without endotoxin testing: Using grey-market peptides without an endotoxin test (LAL-test) drastically increases the risk of toxic shock, fever, or severe immune reactions caused by bacterial contamination.
• Neglecting the prolactin and cortisol spike: Ignoring hormonal side effects and dosing too high can lead to systemic stress, lethargy, and in extreme cases, prolactin-induced side effects like gynecomastia.
• Poor injection hygiene: Failing to properly swab the vial septum and injection site with alcohol leads to a high risk of painful subcutaneous abscesses.
• Ignoring nutrient timing: Consuming carbohydrates or fats immediately before or after administration may attenuate the growth hormone pulse, potentially rendering the injection less effective.

Legal Status and Anti-Doping Regulations for GHRP-2

GHRP-2 is explicitly listed as a prohibited doping substance by WADA and in Germany, with no approved medicinal use outside of Japan. Unauthorized sale and use carry legal risks, and anti-doping agencies use mass spectrometry to detect GHRP-2 in blood and urine.

In the EU and Germany, GHRP-2 has no marketing authorization and is categorized as a prohibited peptide with growth hormone-releasing effects. In the USA, it is restricted to experimental research. While possession for personal use may not always lead to prosecution, unauthorized distribution is strictly illegal.